Hanwha Impact invests in U.S.-based Tessera Therapeutics Company's first investment in biotech firm that develops new drugs
이 기사는 2022년 04월 01일 08:06 thebell 에 표출된 기사입니다.Hanwha Impact, formerly known as Hanwha General Chemical, made its first investment in a biotech company that develops new drugs.
The company recently invested in U.S.-based early-stage life sciences company Tessera Therapeutics. The investment is said to be small although financial details have not been disclosed.
Hanwha Impact Global, a subsidiary of Hanwha Impact, executed the investment through Hanwha Impact Partners, using capital commitment made by Hanwha Impact. Hanwha Impact has been very active in investments this year, spending a total of 370 billion won ($305 million) so far.
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source.
Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
The latest investment marks Hanwha Impact and Hanwha Group’s first investment in a biotech company that develops new drugs. Hanwha Impact hinted at a possibility of investing in biotech firms in May 2021 by adding pharmaceuticals, life science and biotechnology to the business purposes listed in the company’s articles of incorporation. After changing its name from Hanwha General Chemical in September 2021, Hanwha Impact made it clear that it will focus more on investment instead of the petrochemical business.
Hanwha Impact invested in Inari Agriculture, which utilizes next-generation gene editing technologies to create resource-efficient corns and soybeans. It also participated in a Series B funding for Catalog Technologies, a DNA-based data storage solution provider.
Hanwha Group hasn’t invested in the new drug development business since its efforts to develop new drugs failed in the 1990s. Market insiders are paying attention to whether the company will gradually restart the business under the control of Kim Dong-kwan, president and chief executive officer of Hanwha Solutions.
The latest investment was led by Hanwha Impact’s investment strategy division. The company hired new managers to handle bio-related investments earlier this year. (Reporting by Eun-jin Choi)
최신뉴스 in 전체기사
- 소니드, 뉴코리아전자통신과 'AI 로봇 재난·위험 방지 사업' 맞손
- '매출 5조' 에코프로, 창사 후 최대 실적 달성
- '수출 확대' 신성이엔지, 영업익 800% 성장 성과
- 롯데케미칼, '우리사주·구주주' 실권 불구 유증 성공
- 최대 4000억 공모채 추진 CJ제일제당, 대표주관만 5곳
- [Korean Paper]보금자리론 급증 대비 주금공, 스트레이트본드 첫 발행
- A급 SK렌터카, 고민 흔적 가득한 '만기·금리밴드' 구성
- SK케미칼, 3년만에 공모채 추진
- [케이뱅크 IPO]상장 철회 공식화…증권업계 "예견된 수순"
- IB 베테랑에 사령탑 맡긴 DB금투, 2018년 돌풍 재현하나
Translated by Kim So-in 의 다른 기사 보기
더벨 서비스 문의
02-724-4102유료 서비스 안내